Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis

Despite progress, 2-year pancreatic cancer survival remains dismal. We evaluated a biomarker-driven, combination/N-of-one strategy in 18 patients (advanced/metastatic pancreatic cancer) (from Molecular Tumor Board). Targeted agents administered/patient = 2.5 (median) (range, 1–4); first-line therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaya, Justin, Kato, Shumei, Adashek, Jacob J., Patel, Hitendra, Fanta, Paul T., Botta, Gregory P., Sicklick, Jason K., Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860045/
https://www.ncbi.nlm.nih.gov/pubmed/36670111
http://dx.doi.org/10.1038/s41525-022-00346-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860045/
https://www.ncbi.nlm.nih.gov/pubmed/36670111
http://dx.doi.org/10.1038/s41525-022-00346-5

Ejemplares similares